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Policy aspects of chemicals testing initiatives and alternatives

An Evaluation of the US High Production Volume (HPV)
Chemical-testing Programme: A Study in (Ir)Relevance,
Redundancy and Retro Thinking
Andrew Nicholson,1 Jessica Sandler2 and Troy Seidle2
1Independent

Consultant; 2People for the Ethical Treatment of Animals, Norfolk, VA, USA

Summary — Under the US Environmental Protection Agency (EPA) High Production Volume (HPV)
Challenge Programme, chemical companies have volunteered to conduct screening-level toxicity tests on
approximately 2800 widely-used industrial chemicals. Participating companies are committed to providing
available toxicity information to the EPA and presenting testing proposals for review by the EPA and posting on the EPA Web site as public information. People for the Ethical Treatment of Animals (PETA) and a
coalition of animal protection organisations have reviewed all the test plans submitted by the participating chemical companies for compliance with the original HPV framework, as well as with animal welfare
guidelines issued by the EPA in October 1999. Our review found major and recurring flaws in the programme’s execution, as well as in its fundamental design. Approximately 75% of the test plans reviewed
violated fundamental terms of the programme. Many participating companies failed to conduct comprehensive analyses of available data and instead proposed superfluous and meaningless tests. The US HPV
programme’s exclusion of human health and exposure data has led to numerous examples of irrelevant
experiments that will not affect how a chemical substance is used or handled. Contrary to claims by both
the EPA and Environmental Defense that few new animal tests are being performed, an estimated 100,000
animals have already died in this US Government-sponsored animal-testing programme.
Key words: animal testing, animal welfare, category testing, chemical screening, chemical testing, EPA,
exposure assessment, hazard assessment, high production volume, HPV, OECD, SIDS.
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Introduction
The USA defines high production volume (HPV)
chemicals as those which are manufactured, sold, or
imported in volumes of one million pounds or more
per year. In response to pressure from the advocacy
group, Environmental Defense (ED), which asserted
that there was a “virtual vacuum of information” on
the 2800 most widely used chemicals in the USA (1),
the US Environmental Protection Agency (EPA)
entered into a series of closed-door meetings with ED
and the American Chemistry Council (ACC), the
product of which was the HPV Challenge
Programme. According to the EPA, the goal of the
HPV programme is to “prioritise chemicals for further testing” (2) by generating basic toxicity data in
line with the OECD “screening information data set”
(SIDS; 3). This is a screening level testing programme
employing, as ED stated, “dumbed-down toxicology”
(1). Despite the fact that upwards of 1400 animals
may be killed for each chemical that undergoes a full
SIDS battery of tests (4), most US animal protection
organisations were never notified of the existence and
development of the HPV programme.
One of the major assumptions underlying the
HPV programme is that chemicals produced in

large volumes pose a greater hazard, on average,
than other substances. However, Cunningham &
Rosenkranz (5) have documented, by using computerised structure–activity relationship analysis, that
“for all toxic effects (including mutagenicity, genotoxicity, carcinogenicity, and developmental toxicity) except one (the in vitro induction of [sister
chromatid exchanges]), the proportion of chemicals
predicted to be toxic among the HPV sample was
significantly less than the proportion of chemicals
predicted to be toxic in the [non-HPV] reference
set”. Likewise, the popular assumption that substantial “knowledge gaps” exist (1) does not withstand even a cursory review of the published
literature for HPV chemicals (6–8). Had the EPA
adhered to normal US government procedures and
subjected the HPV programme to peer review and
public comment, such pertinent information could
have been used to objectively assess the true magnitude of the perceived problem and circumvent the
massive animal testing programme now in place.
As a result of targeted campaigning by People for
the Ethical Treatment of Animals (PETA), once the
existence of the HPV programme became public
knowledge, the US Government negotiated an
agreement among the animal protection commu-
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nity, EPA, ACC, ED and the American Petroleum
Institute (API), to incorporate certain minimal animal welfare measures into the HPV programme.

Animal Welfare Guidance
The basic components of the October 14, 1999, animal welfare agreement (9) are as follows:
Avoiding checklists:
In analysing the adequacy of existing data, participants shall conduct a thoughtful, qualitative analysis
rather than use a rote checklist approach. Participants may conclude that there is sufficient data,
given the totality of what is known about a chemical
. . . that certain endpoints need not be tested.
Using existing data:
Participants shall maximise the use of existing . . .
data to minimise further testing . . ..
Using categories:
Participants shall maximise the use of scientifically
appropriate categories of related chemicals and
structure–activity relationships.
Testing only when relevant:
Before generating new information, participants
should further consider whether any additional
information obtained would be useful or relevant.
In vitro genotoxicity testing “encouraged”:
Participants are encouraged to use in vitro genetic
toxicity testing . . . unless known chemical properties
preclude its use.

3. Testing compounds with known or easily anticipated toxicities.
4. Testing for endpoints in a data rich environment, rather than analysing the universe of
available data which would provide more
insight into toxicity than the crude, screening
level SIDS tests.
5. Testing without coordinating with other industries on similar substances.
6. Testing in vivo when in vitro tests are available.
The following are a few examples taken from the
test plans and public responses posted on the EPA’s
HPV Web site (10).
Failure to consider human use and exposure
data
The EPA consistently ignores human use and exposure data under the HPV programme, insisting
instead that companies conduct tests on substances
for which there is extensive past experience with
human exposure through occupational, household
or consumptive (food, water, air) exposure.
Examples include additional testing of the following
substances:
1.

1,3-Butadiene, even though it has been identified as a carcinogen, primarily through analysis
of human exposure data from industrial settings.

2.

Hydraulic fluids (such as trixylenyl phosphate),
which are documented neurotoxicants and are
therefore carefully managed substances. The
toxicity of these substances is well documented
in worker exposure data.

3.

Many HPV substances are registered with the
US Food and Drug Administration (FDA) as
“Generally Recognised as Safe” (GRAS). These
compounds generally have extensive databases
demonstrating their lack of toxicity, and are
found in many foods consumed each day. Yet
Dupont, for example, proposed additional animal testing on adipic acid, which is GRAS and
had already been found to be safe for use as a
food additive in powdered drink mixes, puddings, and candies.

4.

Many HPV substances are naturally occurring
compounds, the biologic production and human
metabolism of which are well understood, and
which have an extensive history of human consumption. Yet, for example, The Pine Chemical
Association (PCA) is conducting fish acute tox-

Analysis of Compliance
A coalition of US animal protection organisations has
reviewed all the 150 test plans submitted to date
under the EPA’s HPV programme, and has submitted
comments on every one that has called for more animal testing, as well as on a number with no further
proposed animal testing. (Note added in proof: as of
August 2003, more than 220 test plans had been
reviewed.) Approximately 75% of the submitted HPV
test plans violated one or more fundamental aspects of
the October 1999 animal welfare agreement (7). In so
doing, numerous redundant, irrelevant, and useless
animal tests have been proposed and conducted. In
general, these tests fall into the following categories:
1. Testing without considering human exposure
data.
2. Testing for secondary, irrelevant endpoints,
when the primary hazard associated with the
substance is high and well known.
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icity and mammalian developmental toxicity
testing on rosins and rosin salts, despite the
fact that the material is insoluble, is a naturally
occurring substance found primarily in pine
trees, and is regulated by the FDA as a food
additive, on which there is already extensive
experience. Another example is the ionone
derivative category, which are substances
found mainly in plants containing β-carotene.
Human exposure is more likely to occur via
consumption of natural fruits, vegetables, and
nuts than from products flavoured with the
ionone derivatives. The original HPV test plan
did not propose any animal testing; nonetheless the EPA called for additional developmental toxicity testing in its response to the test
plan.
Testing for irrelevant endpoints when the
primary hazard is high and well known
A number of companies have insisted on testing
compounds with primary hazards which are already
well known and well documented. However, if a
compound is tightly regulated and exposure is
extremely limited due to overwhelming obvious
hazards, it makes little sense to conduct further
crude, screening level studies on the compound.
The most obvious substances that fall into this
category are explosive compounds. Many petroleum-derived and chemical feed stream gases are
part of the HPV programme, including butane, 1,3
butadiene, methane, and isoprene, as well as complex streams containing these compounds and others. The ACC’s test plan for crude butadiene
proposed that acute toxicity testing be conducted on
butadiene streams, and the API’s test plan for
petroleum gases proposed acute, repeat-dose, reproductive, and developmental toxicity studies on
ethane, butane, propane, and isobutane. Existing
data generally show no observed effect levels
(NOELs) for these compounds at levels above 5%;
however, the lower explosive limit (LEL), the concentration at which a gas will explode when ignited,
generally ranges between 1% and 4% for these
gases. Furthermore, many of these gases have been
studied as human anaesthetics in the past, and
existing toxicity data show that they act primarily
as simple asphixiants at levels exceeding 15%. The
proposals to conduct additional testing on such
compounds ignore the most obvious hazard — their
explosive nature — which already dictates how they
are managed.
Many other compounds in the HPV programme
are tightly regulated, and exposure to them is generally prevented, based on some specific toxicological properties of the compounds. For example,
further screening-level testing has been proposed
for a number of known carcinogens, despite the fact
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that human exposure is already extremely limited
on the basis of existing knowledge of their more
serious adverse effects. As mentioned above, 1,3
butadiene is regulated at levels less than 2ppm in
industrial settings, but additional reproductive and
subacute (repeat-dose) studies have been proposed
to evaluate the hazard of several butadiene
streams.
Many compounds in the HPV programme are
also strong acids, bases, or oxidants, and are therefore extremely corrosive. For example, spent pulping liquor, a hydrogen sulphide-bearing strong base
containing dissolved lignins and tannins, is obviously corrosive to any organism with which it comes
into contact. Yet additional fish acute toxicity testing has been proposed and will be conducted.
Because of the substance’s high pH, a neutralised
form will be used for testing, thus rendering the
results irrelevant to the starting material. A similar
situation exists with cyclic anhydrides, which are
unstable in water and immediately hydrolise to
form strong acids. Even though these compounds
are already well-known to be toxic, blinding, and
corrosive, and are therefore tightly regulated with
extremely limited exposures, the EPA endorsed the
Industrial Health Foundation’s plan to conduct a
90-day repeat-dose study and a reproductive and
developmental toxicity study on these agents.
Testing compounds with known toxicities
Many substances in the HPV programme are mixtures of previously characterised compounds, the
toxicities of which are already well known. Some
proposed tests are unnecessary, since the answer
can easily be anticipated and the results of the test
will have little bearing on the ultimate regulation of
the compound. For example, it is well known that
hydrocarbons kill fish via non-polar necrosis, an
effect that has little dependence on the specific
structure of a compound. However, both the ACC
and the EPA called for the acute aquatic testing of
fuel oils, because there have been no tests of industrial streams with the same specific compositions.
The additional tests will kill fish at similar levels to
other hydrocarbons, but the checklist will be completed for the compound.
Lack of contextual analysis
Perhaps the greatest failing of the HPV programme
is the failure to seriously examine existing data on
related compounds (both HPV and non-HPV substances) prior to proposing testing. Because of the
failure to develop appropriate categories and consider all existing data, information and understanding are lost. Moreover, when companies do take a
broader view of the toxicity of substances by form-
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ing a category for the compounds, the EPA commonly rejects the category because it fails to meet
the agency’s narrow standard of analysis. To date,
the EPA has objected to at least 27 of the 46 categories on which it has submitted comments. As a
result, participants in the HPV programme are
driven toward conducting more tests and simply
“checking boxes”, noting that all the SIDS endpoints are being fulfilled.
The process of analysing compounds in context
is quite straightforward. Obvious, known hazards should be identified. Trends in similar compounds and their behaviours should be
examined. The chemical and physical properties
of the compounds should be understood before
conducting new tests. Non-sensical endpoints,
including chemically, physically, environmentally, and toxicologically irrelevant endpoints
should not be assessed. Yet the PCA, for example, has repeatedly proposed conducting aquatic
toxicity studies on compounds that are not soluble in water. The PCA has also proposed testing
components of fish oils on fish, as in its test plan
for tall oil fatty acids. A further example of an
HPV test plan that completely fails to evaluate
context is the plan to test trixylenyl phosphate.
This compound is one of more than 20 phenyl
phosphate compounds in the HPV programme,
all of which are commonly used as antioxidants,
stabilisers, and hydraulic fluids. However, the
test plan’s sponsor provides no information on
the use and toxicity of this compound, and simply
calls for testing of all SIDS endpoints, a plan
with which the EPA concurred.
With poorly characterised compounds, it is senseless to conduct any toxicity tests until fundamental
information on boiling point, water solubility,
hydrolysis, vapour pressure, and Kow are known. In
many cases, simply knowing the properties of a
compound can preclude the need to conduct any
further tests. Yet General Electric (GE), for example, submitted several test plans that failed to provide information on even these basic parameters
and that nevertheless proposed extensive animal
testing.
Failure to coordinate across industries
Different industries are not cooperating on test
plans for similar substances, resulting in the performance of numerous redundant tests. For example, the petroleum coke test plan, submitted by the
American Petroleum Institute, analyses two substances that are nearly identical in composition to
carbon black (used in the rubber, plastics, and dye
industries), anthracite coal (widely used as a fuel
and having extensive human industrial exposure
data), and coal coke (used in the steel industry).
The extensive human data on exposure to these

similar substances are not mentioned in the test
plan, and the sponsors are planning to conduct
additional reproductive and developmental toxicity
studies on animals.
In its proposal to re-test tall oil fatty acids, the
PCA failed to recognise that that many of the individual components of fatty acids, including palmitic
acid, stearic acid, oleic acid, and linoleic acid, are
being sponsored through the HPV programme by
the Soap and Detergent Association. Clearly, these
chemicals should have been combined into a single
category under one HPV test plan. The lack of
inter-industry cooperation leads directly to
increased animal testing.
The API’s test plan for the gasoline blending
streams category proposed additional subacute
(repeat-dose) and reproductive/developmental testing of streams high in naphthenes. The sponsor
ignored the fact that benzene, toluene, and xylenes
are the primary toxicants in gasoline streams, and
that these compounds essentially drive all the hazard/risk assessments of the gasoline streams in the
API’s category. Abundant information exists on the
potential hazards associated with streams containing naphthenes, and further testing will neither
contribute to a meaningful increase in knowledge
on the hazards of these compounds, nor change the
manner in which they are regulated. The API also
failed to expand its category to include the compounds in the ACC’s low benzene naphtha category.
As noted in the ACC’s naphtha category test plan,
many of the compounds in that category are also
used in gasoline blending streams. Had the API
maximised the use of chemical categories and coordinated across industries, it could have reduced the
number of animals used and obtained more insight
into the overall hazard associated with these compounds.
Failure to use in vitro methods
Genetic toxicity
The October 1999 agreement specifically calls for
the use of internationally accepted in vitro tests for
genotoxicity — which include the Ames/bacterial
reverse-mutation test, as well as in vitro tests for
chromosomal aberration, cell gene mutation, and
sister chromatid exchanges (OECD Test Guidelines
471, 473, 476 and 479, respectively; 4). The use of
these assays, alone or in combination, has been
found to be highly sensitive to the detection of genotoxicants (11–12). Despite the scientific and ethical
considerations favouring the use of in vitro methods
for this endpoint, numerous in vivo genetic toxicity
tests have been proposed by companies and
endorsed by the EPA (10). The companies and
organisations proposing to conduct the genetic tox-
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icity test in vivo include GE, FMC Corporation,
ExxonMobil, the PCA, the API, and the ACC.
Acute fish ecotoxicity
To date, the EPA continues to reject the use of
viable in vitro assays for the assessment of acute
toxicity to fish (10). One alternative that has been
repeatedly proposed is the TETRATOX assay,
which uses the protozoan, Tetrahymena, as a biomarker for aquatic toxicity in ecological risk assessments (13). The biochemistry and physiology of
Tetrahymena have been thoroughly investigated
since the 1950s, and Tetrahymena, and especially T.
pyriformis, have been used for aquatic toxicity testing since the 1970s. Moreover, the genomics of the
organism are currently being elucidated. The T.
pyriformis population growth test is rapid, inexpensive and has considerable breadth. Data generated
by the TETRATOX assay demonstrate a consistently high degree of concordance to data from
acute toxicity studies in fish.
Another promising in vitro assay is a fish egg test
(14), which exposes very early developmental stage
embryos to concentrations of a test substance. This
test has recently been accepted in Germany as a
replacement for the use of fish in the assessment of
waste-water effluent, and is being proposed as a
total replacement to all uses of fish in acute ecotoxicity studies.
In addition, ECOSAR (ecological structure–activity relationships), an in silico model used to predict
chemical toxicity to aquatic organisms, has been
vastly underused in the HPV programme, despite
explicit guidance from the EPA (15). The model is
capable of predicting effects on a range of taxonomic groups, including fish, invertebrates, and
algae, as well as effects following both acute and
chronic exposure (16).
Developmental toxicity
An embryonic stem cell test (EST) has recently
been validated by the European Centre for the
Validation of Alternative Methods (ECVAM) as a
test for embryotoxicity — a critical parameter and
manifestation of developmental toxicity (17). The
test uses rodent-derived stem cells, which survive in
culture indefinitely and are capable of differentiation. Embryotoxicity is determined by the concentration of a test chemical required to inhibit
differentiation by 50%, together with growth inhibition by 50% relative to controls. This validated
test method is ideally suited for immediate use as a
reduction measure in a basic, screening-level programme like the EPA’s HPV Challenge — whereby
chemicals that test positive for embryotoxicity
could be classified as probable developmental toxi-
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cants without further testing. Despite its enormous
potential as a reduction measure — which would
spare the lives of the more than 1300 animals used
in a standard prenatal developmental toxicity study
according to OECD 414 (4) — the EPA and the participating companies have refused to make use of
this test under the HPV programme (10).
Acute mammalian toxicity
Participants at an October 2000 international
workshop on in vitro methods for assessing acute
systemic toxicity concluded that two basal cytotoxicity assays using normal human keratinocytes
(NHK) and mouse fibroblast (Balb/c 3T3) cell
lines were suitable for immediate use as a reduction measure to calculate starting doses in vivo
(18–19). Spielmann and colleagues (20) have
reported that their use has the potential to reduce
animal use by up to 40%. The EPA subsequently
issued guidance to HPV programme participants
(21) urging them to use this strategy in the generation of acute toxicity data under this programme. However, companies proposing to
conduct acute toxicity testing have frequently
ignored the recommended use of in vitro cytotoxicity assays as a dose-setting measure — even
those proposing to test known non-toxic materials
(10). To date, the EPA has taken no remedial
action in this matter.

Toll in Animal Lives
A review, completed in October 2002, summarised all
the animal tests proposed to date in HPV test plans,
as well as those requested by the EPA over and above
those proposals. Calculations based on the OECD
Guidelines for the Testing of Chemicals (4) suggest
that the total number of animals already killed in the
US HPV programme is approximately 100,000.
Whilst the EPA continues to claim that few new animal tests are being conducted under the HPV programme (22), this is clearly not the case, as fully half
of all the test plans submitted proposed to conduct
additional animal testing. Our conservative estimate
found that more than 250 new animal tests have been
conducted to date, resulting in the wasting of this
inordinately high number of animal lives. Because
the HPV programme began with category testing and
data-rich compounds, the number of animals killed as
the programme continues can also be expected to
climb dramatically.

Conclusions
The US EPA is ignoring the 1999 animal welfare
agreement and has repeatedly encouraged a check-
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the-box approach to testing under the HPV programme. Even though a thorough analysis of existing data would be adequate for ranking the hazards
of many of the HPV compounds, companies propose
the performance of numerous irrelevant tests to
satisfy EPA demands. The exclusion of human use
and exposure experience, the insistence on testing
for all endpoints (including for GRAS chemicals),
and the failure to approve proposed category testing, have led to testing for endpoints that are chemically, physically, and/or toxicologically irrelevant.
In vitro screening tools are being ignored, whilst
tests that are not a part of the HPV programme are
repeatedly proposed (e.g. skin and eye irritation,
chronic fish and terrestrial ecotoxicity, 90-day
repeat-dose tests, and studies via the dermal exposure route).
The EPA has clearly exhibited a double standard
with regard to animal testing in its responses to
proposed HPV test plans. In general, the EPA presumes that more animal testing is required. No justification is required if a company plans to use
animal tests — even when the company has clearly
ignored existing data — whilst there is disproportionate scrutiny of all proposals to use categories,
structure–activity relationship analyses or existing
data, in order to avoid further testing on animals.
The EPA ignores the comments submitted by the
animal protection community and does not require
adherence to the most basic animal welfare principles. In a number of instances, the EPA has posted
its own comments prior to the deadline for public
comments, thus ensuring that public comments are
not taken into consideration.
The US HPV programme lacks a contextual
framework, which is necessary in order to prioritise and understand toxicity and chemical hazards. It defaults to a check-the-box approach,
which simply ensures compliance with bureaucratic mandates, but does very little to protect
public health and the environment. Its reliance
on a simple checklist approach leads to overconfidence in hazard assessment instead of demanding
a serious review of existing physical, chemical,
exposure and toxicological information. Conclusions may be reached based on irrelevant tests
or tests which are essentially worthless in extrapolating to humans, due to dramatic interspecies
variability, lack of consideration of exposure
pathways, or lack of understanding of the fundamental properties of a compound. The HPV programme is therefore resulting in a large number
of animal deaths for precious little useful information.
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